Inspire Medical Systems, Inc. (NYSE:INSP) receives a "Buy" rating from Stifel Nicolaus with a price target of $110, indicating a potential increase of 22.4%.The company is currently facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934.Despite legal challenges, INSP's stock price shows an increase, with a current price of $89.87 and a trading volume of 1,073,158 shares on the NYSE.Inspire Medical Systems, Inc. (NYSE:INSP) is a company that specializes in innovative medi ...

MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025. Inspire is scheduled to present at 11:30 a.m. Eastern Time. The presentation will be accessible via a live ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $224.5 million, a 10% increase from $203.2 million in Q3 2024 [15] - U.S. revenue was $214.4 million, up 9% from $195.8 million in the prior year [15] - Gross margin improved to 85.8% from 84.1% year-over-year, driven by increased sales volume and a favorable sales mix of Inspire 5 [15] - Operating income decreased to $9.6 million from $14.3 million in the prior year [16] - Net income for the quarter was $9.9 million, down from $18.5 million year-over-year [16] - Adjusted EBITDA was $44 million, slightly down from $44.5 million in the prior year [17] - The company increased its earnings per share guidance to $0.90-$1, up from $0.40-$0.50 previously [9] Business Line Data and Key Metrics Changes - Inspire 5's U.S. launch showed significant progress, with physician training over 98% complete and contracting over 90% complete for centers [8] - The Inspire 5 system demonstrated an 87% inspiratory overlap with patients' breathing, indicating strong clinical performance [5] - The company reported a 20% reduction in surgical times based on clinical studies [4] Market Data and Key Metrics Changes - Revenue outside the U.S. was $10.1 million, a 37% increase year-over-year [15] - The Centers for Medicare & Medicaid Services (CMS) finalized an 11% increase in the physician fee schedule for CPT code 64568, effective January 1, 2026 [10] Company Strategy and Development Direction - The company remains focused on patient outcomes and innovation, investing in clinical evidence and medical education [4] - Strategies include training advanced practice providers and increasing the capacity of provider partners to treat more patients [13] - The company is optimistic about the future, with plans to drive long-term stakeholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of growth heading into 2026, with an early indication of 10%-11% growth for next year [22] - The company is mindful of near-term factors such as inventory transitions and competitive activity but remains focused on executing its growth strategy [23] - Management highlighted the positive impact of GLP-1s on patient flow into clinics, which could benefit Inspire therapy [12] Other Important Information - The company completed $50 million in share repurchases during the quarter, totaling $125 million year-to-date [17] - The company ended the quarter with $411 million in cash and investments, allowing for continued investment in growth strategies [17] Q&A Session Summary Question: Thoughts on 2026 planning and cadence - Management is focused on finishing Q4 strong and is still early in the 2026 planning process, indicating potential accelerated growth from Q3 [22] Question: Trends in business for October and Q4 guidance - Management noted strong trends with Inspire 5 and expects to see consistent execution and operational benefits from tighter integration across departments [28] Question: Transitioning centers to Inspire 5 - Management confirmed that while many centers are transitioning to Inspire 5, some will continue to use Inspire 4 for economic reasons [32] Question: Operating expenses and sustainability - Management indicated that while there is a focus on expense control, investments in R&D and marketing will continue, with a disciplined approach to spending [36] Question: Impact of new competitors on market growth - Management stated that it is early days for new competitors and they will continue to monitor the situation closely [64] Question: Economic considerations for centers using Inspire 4 - Management clarified that economic factors are more related to site of service reimbursement rather than physician reimbursement rates [82] Question: Operating expenses trend for 2026 - Management expects a slight increase in DTC spending but does not anticipate it to grow at the same rate as revenue [83]

MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2025. Recent Business Highlights Generated revenue of $224.5 million in the third quarter of 2025, a 10% increase over the same quarter last yearAchieved gross m ...

Core Insights - Inspire Medical Systems, Inc. is set to present at the 2025 UBS Global Healthcare Conference on November 10, 2025, at 11:45 a.m. Eastern Time [1][2] - The company specializes in innovative, minimally invasive solutions for patients suffering from obstructive sleep apnea [3] Company Overview - Inspire Medical Systems focuses on the development and commercialization of proprietary Inspire therapy, which is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company aims to provide safe and effective treatment options for patients with this condition [3] Presentation Details - The presentation will be available via a live webcast, with a replay accessible for two weeks afterward in the Event Archive section of Inspire's Investor website [2]

Core Viewpoint - Inspire Medical Systems, Inc. is set to release its financial results for Q3 2025 on November 3, 2025, followed by a conference call to discuss these results and recent business developments [1]. Financial Results Announcement - The financial results for the third quarter of 2025 will be released after the close of trading on November 3 [1]. - A conference call will be hosted by Inspire's management team at 5:00 p.m. Eastern Time on the same day to discuss the results [1]. Webcast and Participation - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For those wishing to ask questions, registration is required, and an email will be sent with dial-in details and a unique access code [3]. - The company recommends registering at least 10 minutes before the call to ensure connection [3]. Replay Availability - A replay of the conference call will be accessible on the Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].

Company Overview - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4] - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4] Leadership Change - Chief Financial Officer Rick Buchholz will step down effective December 31, 2025, to pursue other professional opportunities, but will remain in a financial advisory role until February 28, 2026, to ensure a smooth transition [1][2] - Buchholz has been with the company since 2014 and has played a significant role in its growth, including increasing revenue from $4 million to over $800 million in 2024 [2] Financial Guidance - The company reaffirms its full-year 2025 revenue guidance of $900 to $910 million, with a gross margin guidance of 84% to 86% and diluted net income per share guidance of $0.40 to $0.50 [3]

Core Viewpoint - Inspire Medical Systems, Inc. is set to present at the Wells Fargo 2025 Healthcare Conference, highlighting its focus on innovative solutions for obstructive sleep apnea [1][2]. Company Overview - Inspire Medical Systems is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea [3]. - The company's proprietary Inspire therapy is recognized as the first and only neurostimulation technology approved by the FDA, EU MDR, and PDMA for treating moderate to severe obstructive sleep apnea [3]. Event Details - The presentation is scheduled for September 3, 2025, at 11:00 a.m. Eastern Time and will be available via a live webcast [2]. - A replay of the presentation will be accessible for two weeks post-event on Inspire's Investor website [2].

Core Viewpoint - Inspire Medical Systems, Inc. has authorized a share repurchase program of up to $200 million to return capital to stockholders while continuing to invest in growth opportunities, particularly the launch of its next-generation neurostimulation system, Inspire V [1][2]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA) [3]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3]. Financial Strategy - The share repurchase program is based on the company's historical and expected business performance, cash and liquidity position, and market conditions [2]. - The program allows for flexibility in the timing, manner, price, and amount of repurchases, which may occur through various transaction methods [2]. - The share repurchase program is set to expire on August 7, 2027, unless terminated or extended by the Board [2]. Product Launch - Inspire V represents the largest product launch in the company's history, with significant investments in marketing and expansion to support this initiative [2]. - The company expresses confidence in its growth prospects due to low market penetration and believes its stock is undervalued [2].

Core Viewpoint - Inspire Medical Systems, Inc. will release its financial results for the second quarter of 2025 on August 4, 2025, followed by a conference call to discuss these results and recent business developments [1]. Financial Results Announcement - The financial results will be announced after the close of trading on August 4, 2025 [1]. - A conference call will take place at 5:00 p.m. Eastern Time on the same day to discuss the results [1]. Conference Call Details - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For participants wishing to ask questions, registration is required, and an email with dial-in details will be sent after registration [3]. - It is recommended to register at least 10 minutes before the call starts to ensure connection [3]. Replay Information - A replay of the conference call will be available on the Company's Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].